There are currently 74 clinical trials in Huntsville, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including Heart Center Research, Llc, Clearview Cancer Institute, Medical Affiliated Research Center Inc and Pfizer Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of JK07 in Patients With Chronic Heart Failure
NCT06369298
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \> 40% and ≤ 65%.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/07/2025
Locations: Site 138, Huntsville, Alabama
Conditions: Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Register for Updates
Hybrid Type I Effectiveness-Implementation Trial of Project nGage
NCT05723653
Recruiting
The goal of this Hybrid Type I effectiveness-implementation trial is to test Project nGage, an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among young Black men and women ages 18-49.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
02/04/2025
Locations: Thrive Alabama, Huntsville, Alabama
Conditions: HIV Seropositivity
Register for Updates
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
NCT05640102
Recruiting
This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Clearview Cancer Institute, Huntsville, Alabama
Conditions: Waldenstrom Macroglobulinemia
Register for Updates
SYMPHONY-PE Study for Treatment of Pulmonary Embolism
NCT06062329
Recruiting
Evaluation of the Safety and Efficacy of the Symphony Thrombectomy System in the Treatment of Pulmonary Embolism
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/22/2025
Locations: Huntsville Hospital, Huntsville, Alabama
Conditions: Acute Pulmonary Embolism, Thromboembolism, Emboli, Pulmonary, Thrombosis, Thrombus; Embolism, Embolism, Cardiovascular Diseases, Vascular Diseases
Register for Updates
Effects of Ashwagandha Extract on Stress Levels
NCT06793891
Recruiting
The purpose of this study is to evaluate the efficacy of two proprietary ashwagandha extracts on stress levels, with secondary outcomes of cognition, energy, and sleep, as compared to a placebo.
Gender:
FEMALE
Ages:
Between 30 years and 59 years
Trial Updated:
01/21/2025
Locations: Nutraceuticals Research Institute, Huntsville, Alabama
Conditions: Stress
Register for Updates
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
NCT05437588
Recruiting
This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressive and suicidal behavior and on biomarkers (e.g. miRNA) for these disorders.
Gender:
ALL
Ages:
Between 10 years and 24 years
Trial Updated:
01/14/2025
Locations: UAB Huntsville Regional Medical Campus, Huntsville, Alabama
Conditions: Major Depressive Disorder, Suicidal Ideas, Suicide, Attempted, MDD, Depression, Depression, Teen, Depression and Suicide, Depression in Adolescence, Suicide
Register for Updates
MicroRNA Correlates of Childhood Maltreatment and Suicidality
NCT04923685
Recruiting
This is a research study to find out if childhood trauma and stress are associated with depression or suicidal risk. The study will assess the effects of both short-term and long-term stress on biomarker (e.g. miRNA \[MiRNA\]) levels. miRNAs are a type of RNA (genetic material that is translated into protein) that are found in throughout the body and blood. They are called microRNA because their size is much smaller than typical RNA molecules. miRNAs are highly responsive to environment. This re... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/14/2025
Locations: UAB Huntsville Regional Medical Campus, Huntsville, Alabama
Conditions: Major Depressive Disorder, Suicidal Ideation
Register for Updates
The ENCIRCLE Trial
NCT04153292
Recruiting
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Heart Center Hospital, Huntsville, Alabama
Conditions: Mitral Regurgitation, Mitral Valve Insufficiency
Register for Updates
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT04981795
Recruiting
The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Clearview Cancer Institute, Huntsville, Alabama
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
NCT03887715
Recruiting
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: UAB Huntsville Regional Medical Center, Huntsville, Alabama
Conditions: Treatment Resistant Depression
Register for Updates
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
NCT05166889
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior... Read More
Gender:
ALL
Ages:
Between 40 years and 130 years
Trial Updated:
11/27/2024
Locations: Research Site, Huntsville, Alabama
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)
NCT05633654
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Clearview Cancer Institute, Huntsville, Alabama
Conditions: Triple Negative Breast Cancer
Register for Updates